VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Gilead Sciences, Inc. vs Jack Henry & Associates, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisJack Henry & Associates, Inc.
JKHY · Nasdaq
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Jack Henry & Associates, Inc.'s moat claims, evidence, and risks.
View JKHY analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 59 / 100 for Jack Henry & Associates, Inc.).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); Jack Henry & Associates, Inc. has 3 segments (36.8% in Payments).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; Jack Henry & Associates, Inc. has 7 across 3.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Jack Henry & Associates, Inc.
Payments
Payment processing and transaction services for financial institutions (card, ACH, bill pay, faster payments, settlement support)
United States
Banks, credit unions, and their accountholders; businesses via FI clients
Processor and settlement/risk services provider
36.8%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
Jack Henry & Associates, Inc. strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Jack Henry & Associates, Inc. segments
Full profile >Core
Oligopoly
Payments
Competitive
Complementary
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.